Julianna Lisziewicz

This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (March 2018)

Julianna Lisziewicz (born 1959) is a Hungarian immunologist. Lisziewicz headed many research teams that have discovered and produced immunotheraputic drugs to treat diseases like cancer and chronic infections like HIV/AIDS. Some of these drugs have been successfully used in clinical trials.

Education

Lisziewicz graduated from

Lisziewicz worked at the National Institutes of Health (NIH) from 1989 to 1995. During her time working at the National Cancer Institute she was the Head of the Antiviral Unit at the Laboratory of Tumor Cell Biology.

Research Institute for Genetic and Human Therapy (RIGHT)

In 1995, Lisziewicz and her colleague Franco Lori founded the Research Institute for Genetic and Human Therapy (RIGHT), where Lisziewicz worked as the Director. RIGHT is a non-profit organization based in the United States and Italy that funds research to develop immunologic technologies, create new therapies, and research vaccines for many chronic diseases like HIV/AIDS. RIGHT strives to quickly put their discoveries to use in patient treatments.^[1]

Genetic Immunity, Inc.

Lisziewicz founded Genetic Immunity, Inc., and worked as the President and the CEO of the company. Genetic Immunity is a private clinical-stage biotechnology company in the United States and Hungary. Genetic Immunity works to create and commercialize immunotherapeutic biologics to treat chronic viral infections, allergies, and cancers to prolong the life of the patient and improve their quality of life.^[2]

TREOS Bio

TREOS Bio is a company that develops precision vaccines to treat and prevent cancer using computational immune-oncology. Lisziewicz worked as the Chief Scientific Officer of TREOS Bio.

Research

Antisense oligonucleotides

While working at the National Institute of Health, Lisziewicz worked to find a gene therapy approach to treat HIV/AIDS. She based her research on discovering if small portions of gene-stopping DNA (called antisense oligonucleotides) could be created to bind up the viral RNA in retroviruses like HIV so that the virus could not make more copies of itself to continue the infection. Small pieces of messenger RNA (or mRNA) carry a copy of the cell's DNA to the ribosomes where the mRNA directs the ribosomes to create the proteins that the cells need. Viruses (like HIV) have their own set of mRNA, and they use the ribosomes of the cell they infected to make new viruses to propagate the infection throughout the body. Lisziewicz's idea was to create antisense oligonucleotides that are complementary to the HIV's viral mRNA. These complementary DNA pieces can bind to the HIV viral mRNA and prevent the HIV virus from replicating itself. The use of antisense oligonucleotides worked very well in cell cultures, and was quickly transferred to clinical trials.^[3][4]

DermaVir

DermaVir immunotherapy was created during Lisziewicz's research at the National Cancer Institute in Bethesda, Maryland. She worked to produce gene and antisense therapies to treat HIV/AIDS, and researched how the immune system controls HIV in tissue culture and in monkey models. She applied these results to the treatment of HIV patients in clinical trials. Lisziewicz discovered and headed the preclinical and clinical development of DermaVir HIV immunotherapy. Under Lisziewicz's direction, DermaVir successfully completed a Phase 2 clinical trial.^[5]

DermaVir is a topical vaccine that is applied with a patch to the skin. It is a new immunization strategy that uses dendritic cells to increase viral antigen production. DermaVir contains a plasmid that expresses all of the HIV proteins except integrase. This stimulates an immune response to attack the cells infected with HIV.

DermaVir has been proven safe and immunogenic in several clinical trials, one of which was in collaboration with the Division of AIDS (DAIDS). In one trial, Lisziewicz's research team compared the

An investigation Lisziewicz was involved with when she was working at TREOS Bio is how human leukocyte antigen (HLA) genes regulate immune responses. This research led to the development of a computational immune-oncology technology that can determine a patient's natural T cell response to tumor antigens. As a result, TREOS Bio found there was a correlation between a patient's HLA gene sequence and how well their immunotherapies worked. PolyPEPI™ immunotherapies to treat a number of cancer indications were created by TREOS Bio using the computational immune-oncology. ^[7]

Langerhans cell-targeting DNA vaccines